Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
- 30 August 2002
- journal article
- Published by Springer Nature in Leukemia
- Vol. 16 (9) , 1664-1667
- https://doi.org/10.1038/sj.leu.2402629
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 15 references indexed in Scilit:
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosisHuman Mutation, 2001
- Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignanciesSeminars in Hematology, 2001
- Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trialBlood, 2001
- Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumorsAnti-Cancer Drugs, 2001
- JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cellsBritish Journal of Haematology, 2000
- Farnesyltransferase Inhibitor Induces Rapid Growth Arrest and Blocks p70s6k Activation by Multiple StimuliPublished by Elsevier ,2000
- IL-6 up-regulates Mcl-1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathwayEuropean Journal of Immunology, 1999
- Non-Ras targets of farnesyltransferase inhibitors: focus on RhoOncogene, 1998
- Multiple MyelomaNew England Journal of Medicine, 1997
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988